Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call

Rhea-AI Summary

Simulations Plus (NASDAQ: SLP) will announce its financial results for the second quarter of fiscal year 2023 on April 5, 2023, after the market closes. The company has been a leader in the biosimulation market for over 25 years, providing software and consulting services to drug discovery and development sectors. Interested stakeholders can listen to the conference call at 5 p.m. EDT on the same day, with access via a live webcast or phone call. For more information about the company's services and initiatives, visit their official website.

Positive

• Simulations Plus has over 25 years of experience in the biosimulation market.
• The company's technology is licensed by major pharmaceutical and biotechnology firms.

Negative

• None.

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wednesday, April 5, 2023.

The Company will host a conference call on April 5, 2023, at 5:00 p.m. Eastern Time. All interested parties are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 877-451-6152 (domestic) or 201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the Investors page of the Simulations Plus website where it will also be available for replay approximately one hour following the call.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report

View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005464/en/

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Hayden IR

Mr. Brian Siegel

346-396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

When will Simulations Plus report its Q2 2023 financial results?

Simulations Plus will report its financial results on April 5, 2023.

What time is the Simulations Plus conference call?

The conference call will be held at 5 p.m. EDT on April 5, 2023.

How can I access the Simulations Plus conference call?

The conference call can be accessed via a live webcast or by calling 877-451-6152 for domestic or 201-389-0879 for international.

What is the financial period for Simulations Plus's upcoming report?

The financial results will cover the second quarter ending February 28, 2023.